Articles tagged with Vaccine Development
A new research strategy enhances COVID-19 vaccine effectiveness by providing 'border protection' immunity in the nose, mouth and blood. The approach involves suppressing an enzyme that breaks down both pathogens and immune cells, resulting in a robust antibody response and improved protection against infections.
SK bioscience's GBP510 vaccine candidate has shown promising safety and immunogenic response in Phase I/II clinical trials. IVI will partner with SK on global Phase III trials to accelerate development and WHO approval of the vaccine.
A Dartmouth research team led by Glyn Elwyn is testing interactive educational approaches to boost vaccine confidence among unvaccinated long-term care workers. The study aims to measure vaccine confidence, knowledge, and trust in the COVID-19 vaccines.
Researchers developed a θ-SIR model to simulate the impact of SARS-CoV-2 strains and vaccines on COVID-19 propagation. The model estimates that insufficient vaccination rates can lead to new waves, even with effective reproduction numbers below 1.
A new study published in Nature Medicine reveals that willingness to get a COVID-19 vaccine is higher in developing countries, with personal protection being the main reason for acceptance. Concern about side effects was the most common reason for vaccine hesitancy, but health workers were considered trusted sources of information.
Experts debate whether COVID-19 vaccination should be delayed in children due to unclear benefits and risks. Vulnerable people worldwide should be prioritized instead, but some argue that children should not be disadvantaged.
Researchers developed a biomaterial-based infection vaccine (ciVAX) approach to combat infectious diseases. ciVAX vaccines combine two technologies that capture immunogenic antigens from pathogens and reprogram the immune system, offering potential solutions for sepsis prophylaxis, pandemic threats, and biothreats.
A new study found that only 20 out of 51 US states included health equity committees in their COVID-19 vaccine distribution plans, with only 8 representing minority groups. The study highlights the need for standardized processes to address existing healthcare disparities and ensure equitable access to vaccines.
Researchers have uncovered a novel strategy employed by MRSA to evade the immune response, causing toxic effects on white blood cells. A mutated protein-based vaccine shows promise in preventing such toxicity, suggesting a potential cure for deadly MRSA infections.
Researchers at TUM created a low-cost, automated rapid test for detecting SARS-CoV-2 antibodies with high sensitivity and specificity. The test can determine antibody concentrations and has the potential to answer questions about corona immunity, vaccinations, and disease progression.
Researchers at UNC-Chapel Hill developed a universal vaccine that protects against multiple coronaviruses, including COVID-19 and SARS. The hybrid vaccine effectively generated neutralizing antibodies against various spike proteins, preventing infection and lung damage in mice.
Vaccine developers suggest that documented side effects are a byproduct of an effective immune response. The authors argue that fatigue and headache after vaccination should be viewed positively as a necessary step towards herd immunity.
A research team at POSTECH has created a multivalent, adjuvant-free vaccine against various strains of avian influenza. The vaccine uses green vaccine technology to produce bacteria-like particles that elicit strong immune responses in mice and chickens.
UT Extension has received grants from the USDA to combat low vaccination rates in high-risk counties across Tennessee. The initiatives aim to correct misinformation and strengthen vaccine norms through local partnerships and social media outreach.
Dr. Katalin Karikó's groundbreaking research on modifying nucleosides in mRNA led to the development of mRNA vaccines with over 94% efficacy against COVID-19. The Vilcek Prize for Excellence recognizes her contributions to science and medicine.
A new study from the University of Kansas reveals that people flocked to Parler to discuss COVID-19 vaccines in an echo chamber-type environment, where they shared misinformation and reinforced conspiracy theories. The analysis shows that users followed themes and used hashtags to spread their content, highlighting the importance of ad...
The La Jolla Institute for Immunology has partnered with Synbal, Inc. to develop multi-gene, humanized mouse models for COVID-19 research. These new models are expected to provide a better understanding of SARS-CoV-2 infection and disease severity, enabling the development of more effective vaccines and therapies.
Creating an oral antiviral has the potential to fully eradicate COVID-19 by allowing early treatment, preventing hospitalizations and fatalities. However, progress in antiviral development has been slow compared to vaccine development, highlighting the need for continued research.
Researchers at the University of Vermont have discovered new biomarkers for predicting clinical and immune responses to dengue virus infection. These findings could aid in the development of more effective vaccines against all four dengue strains, a crucial step in combating this deadly disease.
A new COVID-19 vaccine developed using the Sementis Copenhagen Vector (SCV) platform is being accelerated for human clinical trials within 18 months. The vaccine aims to provide long-term and broad-ranging immunity against SARS-CoV-2, including mutant strains.
Researchers at Iowa State University have developed a vaccine targeting the SARS-CoV-2 receptor-binding domain to induce potent antibody responses in mice. The approach is relatively easy to produce and scale up, offering advantages over existing vaccines.
A high rate of vaccination is vital to reducing COVID-19 cases and controlling the pandemic, according to new research from the Mayo Clinic. If Minnesota had achieved a 75% vaccination rate by early April, case numbers and hospitalizations would plummet by July.
The article discusses the critical role of Texas Biomed in the development of the Pfizer COVID-19 vaccine through preclinical testing. Scientists tested two mRNA vaccine candidates in rhesus macaques, showing high effectiveness in protecting against SARS-CoV-2, and highlighting the importance of rapid therapy and vaccine development.
A study from Rockefeller University suggests that breakthrough COVID cases may be driven by rapid evolution of the virus. Ongoing testing of immunized individuals is crucial to mitigate future outbreaks.
Researchers are developing an opioid vaccine that targets fentanyl, a potent synthetic opioid, to reduce respiratory depression. The vaccine stimulates the body to create powerful antibodies that bind to opioid molecules, preventing them from reaching the brain and reducing overdose risk.
A new study describes broadly neutralizing antibodies that can prevent and potentially treat tick-borne encephalitis. These antibodies, known as VH3-48, have shown promise in preventing the disease and even treating it, as well as other tick-borne viruses.
A novel nanoparticle vaccine, called spike ferritin nanoparticle (SpFN), is being tested in a Phase 1 clinical trial at WRAIR. The vaccine has shown promise in inducing potent and broad neutralizing antibody responses against SARS-CoV-2 variants.
A new model of the SARS-CoV-2 spike protein reveals potential new vaccine targets, including spots with minimal glycan shielding. The researchers identified novel sites and confirmed their vulnerability through lab experiments.
A UConn researcher has developed a successful Zika vaccine in preclinical studies using a novel platform technology. The vaccine, based on a viral vector and enhanced expression of the virus antigen, was found to mount a strong immune response and protect against Zika virus infection.
Researchers developed a tamper-proof temperature indicator to monitor mRNA vaccine storage conditions. The system can alert healthcare workers when the vaccine reaches an unsafe temperature for a certain period, ensuring effective distribution and use of the vaccine.
Researchers at WRAIR and Duke University have confirmed the effectiveness of monoclonal antibodies against malaria. The study found that certain mAbs showed promise in both culture-based and mouse infection models, suggesting distinct sites on the circumsporozoite protein can be targeted for improved vaccines.
The introduction of immunization passports may help countries reopen and revitalize their economies while reducing the spread of SARS-CoV-2. To implement these passports effectively, governments must establish secure digital immunization records and ensure adherence to international standards.
To ensure an effective global immunization strategy against COVID-19, vaccines must be produced at scale, priced affordably, and allocated globally. The authors assess the potential contribution of leading vaccines using a traffic light system, highlighting production challenges and the need for equitable distribution. Governments and ...
Two scientists urge health agencies to invest in vaccine development based on broadly neutralizing antibodies against multiple virus variants and strains. This approach could provide immunity against emerging pandemics and serve as a pan-virus solution for prevention and treatment.
A team of Chinese scientists, led by Professor Jianping Huang, developed the Global Prediction System of the COVID-19 Pandemic (GPCP) to predict the spread of the disease. The GPCP combines epidemiological data and models using advanced algorithms, achieving better results than traditional methods.
USC researchers have developed an AI-assisted method that can predict and design effective vaccines against the coronavirus in seconds, rather than months or years. The method uses machine learning to analyze potential mutations and pinpoint the best vaccine candidates, which could help combat the evolving virus.
A new DNA-based vaccine platform has been shown to induce potent immune responses in mice, generating high levels of antibodies and strong T cell responses. The vaccine was found to be immunogenic, efficiently neutralizing the SARS-CoV-2 virus after a single immunization.
A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, stimulating the production of rare immune cells needed to generate broadly neutralizing antibodies. The targeted response was detected in 97 percent of participants who received the vaccine.
The COVID-19 pandemic has accelerated scientific innovation, with scientists working at record speed to develop vaccines, diagnose, and treat the virus. Despite these advances, the pandemic has also raised concerns about public trust in science, exacerbated by mixed messaging and politicization.
Researchers at the University of Sydney have developed a novel method to rapidly synthesize safe vaccines using protein-based immunization. The approach demonstrated strong immune response in mice against tuberculosis and has potential applications for respiratory diseases, including COVID-19.
Researchers at the University of Wisconsin-Madison have developed a tool to help prioritize vaccine distribution among people who share similar risks due to their jobs. The algorithm considers both age and socioeconomic status to identify those at greater risk of severe COVID-19 complications.
A new tool predicts viral escape mutations by analyzing the relationship between viruses and human immunity, as well as the structure of sentences in natural language. The algorithm achieves accurate results without prior training, identifying high-escape potential regions in SARS-CoV-2's Spike protein.
A new study suggests that COVID-19 vaccines may be less effective in individuals with depression, stress, loneliness, or poor health behaviors. Engaging in exercise and getting a good night's sleep before vaccination can help boost the immune response.
Researchers reviewed 49 studies linking stress, depression, and poor health behaviors to impaired immune response to vaccination. Improving these factors can enhance the body's response to the COVID-19 vaccine.
Researchers have identified and characterised a new strain of Leishmania parasite to form the basis of a controlled human infection model. The study aims to accelerate vaccine development for this life-threatening disease, which causes slow-to-heal skin ulcers and has no current vaccines or effective treatments.
Researchers developed a new mRNA delivery platform using ZIF-8 nanoparticles that exhibit high mRNA loading capacity, successful endosomal escape, and synergistic GSH depletion. This approach upregulates mRNA translation and improves delivery efficiency compared to existing methods.
Experts discuss microbial-based solutions to combat COVID-19, including vaccine candidates and production platforms. The webinar explores learnings from vaccine development, innovative approaches to address systemic inflammation.
A comprehensive SARS-CoV-2 animal model study has identified two potential models: Indian rhesus macaques and African baboons. The macaque model shows promise for vaccine development, while the baboon model exhibits greater disease progression, making it suitable for evaluating anti-viral therapeutics and co-morbidities.
The Phase 3 trial of Novavax's NVX-CoV2373 vaccine is being conducted in the US and Mexico, enrolling up to 30,000 adults in two cohorts. The trial aims to evaluate the safety and efficacy of the vaccine candidate, which has shown promise in animal tests.
Researchers at the University of Zurich have developed a genetic engineering method to prevent Toxoplasma gondii parasite production, which causes toxoplasmosis. The new technique uses CRISPR-Cas9 gene editing scissors to switch off essential genes responsible for oocyst formation without leaving unwanted traces.
The Advanced Photon Source (APS) has been instrumental in the development of COVID-19 vaccines, allowing for rapid progress through genetic mutations that increase effectiveness. Scientists used APS ultrabright X-ray beams to illuminate virus structures and design vaccine techniques, drugs, and treatments.
Researchers achieved rapid development of effective vaccines against COVID-19, highlighting the collaboration between scientists and governments. However, this unprecedented speed revealed alarming fissures between science and policy makers.
The COVID-19 vaccine candidate, KBP-COVID-19, has demonstrated potential advantages in production speed and stability at room temperature, which could reduce the time between virus identification and vaccine deployment. The Phase I study will enroll 180 healthy volunteers to assess the safety and efficacy of the vaccine.
Researchers at the Ragon Institute have developed a new one-step CRISPR technique to rapidly create mice capable of producing human antibodies. The method dramatically shortens the timeline for generating specialized mice, allowing scientists to accelerate their research and respond more quickly to new developments in the field.
A survey of 788 US adults found that concerns about side effects were a significant barrier to getting the vaccine. Disparities in willingness to get vaccinated also existed among demographic groups, with younger and white respondents more likely to be willing than older and Black respondents.
A new iGIST method detects pertussis toxin levels, reducing animal testing. The method is more effective and enables detection of lower toxin levels than current methods.
A KU Leuven vaccine candidate, RegaVax, has shown promise in protecting against Covid-19 and yellow fever in hamsters and monkeys. The vaccine works after a single dose and offers long-lasting immunity to Covid-19.
The 2020 Golden Goose Award winners made significant breakthroughs in COVID-19 vaccine development, leveraging existing knowledge of coronaviruses and the human immune system. Their research has led to several vaccine candidates currently in Phase 3 clinical trials for effectiveness in preventing COVID-19 infection.
A DNA-based vaccine candidate has been found to be effective in protecting cynomolgus macaques from the Crimean-Congo hemorrhagic fever virus. The vaccine generated protective antibodies and prevented signs of disease in infected animals, offering a promising potential treatment for human patients.
A new microneedle skin patch has been developed by UConn researchers to provide immunization against infectious diseases through a single administration. The patch triggers a high immune response and offers a long-term protection similar to multiple injections.